Xolair 150 MG/ML syringeml
Ended Awarded
- Contract number
- SPE2DB25FZX81
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $4,642
Award facts
- Contract value 100% obligated
- $4,642.20 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a firm fixed-price delivery order valued at $4,642.20 by the Defense Logistics Agency (DLA) on September 4, 2025. The delivery order is for Xolair 150 mg/ml syringes, with an ultimate completion date of September 25, 2025. This award carries no set-aside designation, allowing the vendor to compete on equal footing in the federal procurement marketplace. The place of performance is located in Park Ridge, Illinois.
This delivery order is issued under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with the DLA under the SPE2DB program, a $499.9 billion contract vehicle valid through November 2026 that enables the agency to procure a comprehensive range of pharmaceutical products and medical supplies supporting Department of Defense healthcare facilities worldwide. As a critical supplier in the federal pharmaceutical supply chain, DMS Pharmaceutical Group regularly provides branded and generic prescription drugs, biologics, and medical consumables to military health facilities. Xolair (omalizumab) is a biologic monoclonal antibody used primarily for moderate-to-severe asthma and chronic urticaria treatment, representing the specialized pharmaceutical products the company consistently delivers through its DLA contract portfolio.
Quick answers
Who was awarded contract SPE2DB25FZX81?
SPE2DB25FZX81 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on September 4, 2025.
How much is contract SPE2DB25FZX81 worth?
The government has obligated $4,642 on SPE2DB25FZX81.
Is contract SPE2DB25FZX81 an order under another contract?
Yes. SPE2DB25FZX81 is a delivery order under SPE2DB20D9135, an indefinite delivery contract.
Was contract SPE2DB25FZX81 competed?
The extent of competition for SPE2DB25FZX81 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award